BioNordet GmbH — Frankfurt am Main, Germany For healthcare professionals only
Pharmacological information

ACTIVE INGREDIENTS

Complete technical data sheets for each compound: mechanism of action, pharmacokinetics, route of administration, half-life and pharmacopoeia specifications.

Testosterona Propionato

TP-100
Androgen · Short-acting ester
100 mg/mL
Half-life: 0.8 – 1 day
Route: Intramuscular
View full data sheet →

Testosterona Cipionato

TC-200
Androgen · Long-acting ester
200 mg/mL
Half-life: 8 days
Route: Intramuscular
View full data sheet →

Testosterona Enantato

TE-250
Androgen · Long-acting ester
250 mg/mL
Half-life: 4 – 5 days
Route: Intramuscular
View full data sheet →

Mixtes 250

Mixtes® 250
Androgen · Blend of 4 testosterone esters
250 mg/mL
Half-life: Staggered (0.8 – 15 days)
Route: Intramuscular
View full data sheet →

Nandrolona Decanoato

ND-200
Anabolic · 19-nortestosterone
200 mg/mL
Half-life: 6 – 12 days
Route: Intramuscular
View full data sheet →

Drostanolona Propionato

Drotestin®
Anabolic · DHT derivative
100 mg/mL
Half-life: 2.5 days
Route: Intramuscular
View full data sheet →

Metenolona Enantato

Metestin®
Anabolic · DHT derivative
100 mg/mL
Half-life: 10 – 14 days
Route: Intramuscular
View full data sheet →

Trembolona Acetato

TA-75
Anabolic · 19-nortestosterone
75 mg/mL
Half-life: 1 – 1.5 days
Route: Intramuscular
View full data sheet →

Estanozolol

ST-25
Anabolic · DHT derivative
25 mg/mL
Half-life: 24 hours (injectable)
Route: Intramuscular
View full data sheet →

Metandrostenolona

MD-25
Anabolic · Testosterone derivative
25 mg/mL
Half-life: 4.5 – 6 hours
Route: Intramuscular / Oral
View full data sheet →

Oximetolona

Oximet-50
Anabolic · DHT derivative
50 mg/mL
Half-life: 8 – 9 hours
Route: Intramuscular / Oral
View full data sheet →
TP

Testosterona Propionato

TP-100
DCI: Testosterone Propionate · CAS: 57-85-2
100 mg/mL · Injectable oil solution

Description and mechanism of action

Testosterone propionate is a short-acting ester of testosterone, the primary male sex hormone. It is esterified with propionic acid at the 17-beta position of the steroid ring, conferring rapid release following intramuscular injection.

It acts by binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the cell nucleus and modulates gene transcription. It promotes protein synthesis, nitrogen retention, erythropoiesis and the maintenance of male secondary sexual characteristics. Metabolically, it favors positive nitrogen balance and bone mineralization.

Administration

RouteDeep intramuscular
Injection sitesGluteal, deltoid, vastus lateralis
FrequencyEvery 24 – 72 hours
Therapeutic dose25 – 50 mg every 2–3 days
VehicleCastor oil / sesame oil
Volume per vial10 mL multi-dose
Requires frequent injection due to its short half-life. Ideal for rapid dose titration or treatment initiation.

Pharmacokinetics — Plasma half-life

Plasma half-life0.8 – 1 day (20 – 24 h)
Peak serum level (Tmax)24 – 36 hours post-injection
IM bioavailability~100%
Protein binding98% (SHBG y albúmina)
MetabolismHepatic (CYP3A4, 5α-reductase)
EliminationRenal (90%) and fecal (6%)
Detection time~2 weeks

Pharmacopoeia

ParameterSpecification
Molecular formulaC22H32O3
Molecular weight344.49 g/mol
Melting point118 – 122 °C
Optical rotation [α]D+84° a +90° (dioxano)
SolubilityInsoluble in water; soluble in oils, ethanol, chloroform
Assay (HPLC)97.0 – 103.0% of the declared amount
Total impurities≤ 1.0%
SterilityCompliant (Ph.Eur. 2.6.1)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaPh.Eur., USP, BP
Storage15 – 25 °C, protect from light
TC

Testosterona Cipionato

TC-200
DCI: Testosterone Cypionate · CAS: 58-20-8
200 mg/mL · Injectable oil solution

Description and mechanism of action

Testosterone cypionate is a long-acting ester of testosterone, esterified with cyclopentylpropionic acid. After intramuscular injection, it is deposited in the muscle tissue as an oily reservoir, gradually released by enzymatic hydrolysis of tissue esterases.

Its mechanism of action is identical to that of endogenous testosterone: it binds to the nuclear androgen receptor, activating the transcription of genes responsible for protein anabolism, erythropoiesis, spermatogenesis and the maintenance of bone mineral density. It has androgenic and anabolic activity in a 1:1 ratio.

Administration

RouteDeep intramuscular
Injection sitesGluteus maximus, deltoid
FrequencyEvery 7 – 14 days
HRT dose100 – 200 mg every 1–2 weeks
VehicleCottonseed oil
PreservativeBenzyl alcohol 0.9%

Pharmacokinetics — Plasma half-life

Plasma half-life8 days
Peak serum level (Tmax)24 – 48 hours post-injection
Supraphysiological levelsDays 1 – 4
Return to baseline~14 – 16 days
Protein binding98% (SHBG 40%, albúmina 58%)
MetabolismHepatic (reduction, oxidation, conjugation)
EliminationRenal (~90%) and fecal (~6%)
Detection time~3 months

Pharmacopoeia

ParameterSpecification
Molecular formulaC27H40O3
Molecular weight412.61 g/mol
Melting point98 – 104 °C
Optical rotation [α]D+85° a +92°
SolubilityInsoluble in water; soluble in vegetable oils, ethanol
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.0%
SterilityCompliant (USP <71>)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaUSP, BP
Storage20 – 25 °C, protect from light
TE

Testosterona Enantato

TE-250
DCI: Testosterone Enanthate · CAS: 315-37-7
250 mg/mL · Injectable oil solution

Description and mechanism of action

Testosterone enanthate is an ester of testosterone with heptanoic (enanthic) acid at the 17β position. It is the most prescribed testosterone ester worldwide for male hormone replacement therapy (HRT) due to its predictable and stable pharmacokinetic profile.

After hydrolysis of the ester in muscle tissue, free testosterone binds to the androgen receptor, exerting anabolic effects (protein synthesis, nitrogen retention, IGF-1 stimulation) and androgenic effects (development and maintenance of secondary sexual characteristics, libido, spermatogenesis). It stimulates renal erythropoiesis by increasing erythropoietin production and through direct action on bone marrow progenitors.

Administration

RouteDeep intramuscular
Injection sitesGluteus maximus, vastus lateralis
FrequencyEvery 7 – 28 days (HRT)
HRT dose125 – 250 mg every 1–4 weeks
VehicleCastor oil / sesame oil
PreservativeChlorobutanol or benzyl alcohol

Pharmacokinetics — Plasma half-life

Plasma half-life4 – 5 días
Peak serum level (Tmax)24 – 72 hours post-injection
Duration of action2 – 4 weeks
Protein binding98% (SHBG + albúmina)
MetabolismHepatic (5α-reductase, aromatase CYP19)
Active metabolitesDHT (5α-dihydrotestosterone), estradiol
EliminationRenal (90%), fecal (6%)
Detection time~3 months

Pharmacopoeia

ParameterSpecification
Molecular formulaC26H40O3
Molecular weight400.60 g/mol
Melting point34 – 39 °C
Optical rotation [α]D+77° a +82°
AppearanceWhite to off-white crystalline powder
SolubilityInsoluble in water; soluble in oils, ethanol, ether
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.0%
SterilityCompliant (Ph.Eur. 2.6.1 / USP <71>)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaPh.Eur., USP, BP, JP
Storage15 – 25 °C, protect from light
S4

Mixtes 250

Mixtes® 250
Staggered-release formulation
250 mg/mL total · Injectable oil solution

Composition per mL

EsterConcentrationCASHalf-lifeFunction in the blend
Testosterona Propionato30 mg57-85-20.8 – 1 dayRapid onset of action; peak at 24h
Testosterona Fenilpropionato60 mg1255-49-81.5 – 2 daysEarly intermediate-action bridge
Testosterona Isocaproato60 mg15262-86-94 – 5 daysMid-phase level maintenance
Testosterona Decanoato100 mg5721-91-57 – 15 daysProlonged action; sustains baseline levels

Description and mechanism of action

The blend of four testosterone esters was designed to provide staggered release of the active ingredient. Each ester has a different chain length, which determines its hydrolysis rate and, therefore, the release kinetics of free testosterone.

The propionate provides a rapid peak (24-48h), the phenylpropionate extends the action during the first few days, the isocaproate maintains levels in the intermediate phase, and the decanoate ensures sustained release for 2-3 weeks. The result is a more stable pharmacokinetic profile with fewer peak-trough fluctuations than a single ester.

Administration

RouteDeep intramuscular
Injection sitesGluteus maximus
FrequencyEvery 14 – 21 days
HRT dose250 mg (1 mL) every 2–3 weeks
VehiclePeanut oil
PreservativeBenzyl alcohol
Contraindicated in patients with peanut or soy allergy. Always verify the oily excipient.

Overall pharmacokinetics

First peak (propionate)24 – 48 hours
Sustained plateauDays 2 – 12
Total duration of action21 – 28 days
Apparent half-life~15 days (dominated by decanoate)
MetabolismHepatic after hydrolysis
EliminationRenal and fecal

Pharmacopoeia

ParameterSpecification
Total testosterone base content176 mg equivalent per mL
Individual assay (HPLC)90.0 – 110.0% of each declared ester
Total impurities≤ 1.5%
SterilityCompliant (Ph.Eur. 2.6.1)
Bacterial endotoxins< 10 UE/mL
pH (reconstituted)Not applicable (oil solution)
Pharmacopoeia de referenciaPh.Eur., BP
Storage15 – 25 °C, protect from light
ND

Nandrolona Decanoato

ND-200
DCI: Nandrolone Decanoate · CAS: 360-70-3
200 mg/mL · Injectable oil solution

Description and mechanism of action

Nandrolone decanoate is an anabolic steroid derived from 19-nortestosterone (lacking the methyl group at C-19). This structural change confers an anabolic:androgenic ratio of approximately 10:1, meaning a potent anabolic effect with reduced androgenic activity.

It binds to the androgen receptor but, unlike testosterone, is reduced by 5α-reductase to dihydronandrolone (DHN), a metabolite with lower AR affinity than DHT. This explains its lower incidence of androgenic effects such as acne, alopecia and prostatic growth. It stimulates collagen synthesis, bone calcium retention and erythropoietin production.

Administration

RouteDeep intramuscular
Injection sitesGluteus maximus
FrequencyEvery 7 – 21 days
Therapeutic dose25 – 100 mg every 1–3 weeks
Dose in anemias100 – 200 mg/week
VehicleSesame oil / castor oil

Pharmacokinetics — Plasma half-life

Plasma half-life6 – 12 días
Peak serum level (Tmax)24 – 72 hours
Duration of action2 – 4 weeks
Protein binding~80%
Aromatization~20% relative to testosterone
MetabolismHepatic (5α-reductase to DHN)
EliminationRenal
Detection timeUp to 18 months

Pharmacopoeia

ParameterSpecification
Molecular formulaC28H44O3
Molecular weight428.65 g/mol
Melting point31 – 36 °C
AppearanceWhite to yellowish crystalline powder
SolubilityInsoluble in water; soluble in ethanol, oils
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.0%
SterilityCompliant (Ph.Eur. 2.6.1)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaPh.Eur., USP, BP
Storage15 – 25 °C, protect from light
DP

Drostanolona Propionato

Drotestin®
DCI: Drostanolone Propionate · CAS: 521-12-0
100 mg/mL · Injectable oil solution

Description and mechanism of action

Drostanolone is an anabolic steroid derived from dihydrotestosterone (DHT) with the addition of a 2α-methyl group. This structural modification prevents its metabolism by 3-hydroxysteroid dehydrogenase in muscle tissue, granting it significant anabolic activity that DHT does not possess.

As a DHT derivative, it does not aromatize to estrogens. It possesses moderate anti-estrogenic activity by competing with the aromatase enzyme. Its anabolic:androgenic ratio is 62:25 (reference testosterone = 100:100). It promotes nitrogen retention, protein synthesis and lipolysis without significant water retention.

Administration

RouteIntramuscular
Injection sitesGluteal, deltoid, vastus lateralis
FrequencyEvery 48 – 72 hours
Therapeutic dose100 mg every 2–3 days
Oncology dose (hist.)100 mg 3x/week
VehicleSesame oil
Historically approved for advanced breast cancer in postmenopausal women (Masteril®/Drolban®). Currently discontinued in most pharmaceutical markets.

Pharmacokinetics — Plasma half-life

Plasma half-life2.5 días
Peak serum level (Tmax)24 – 48 hours
Duration of action3 – 4 days
AromatizationNone (DHT derivative)
Conversion to DHTNo (already a DHT derivative)
MetabolismHepatic
EliminationRenal
Detection time~3 weeks

Pharmacopoeia

ParameterSpecification
Molecular formulaC23H36O3
Molecular weight360.53 g/mol
Melting point123 – 130 °C
AppearanceWhite crystalline powder
SolubilityInsoluble in water; soluble in ethanol, oils
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.5%
SterilityCompliant (Ph.Eur.)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaBP (discontinued monograph in USP)
Storage15 – 25 °C, protect from light
ME

Metenolona Enantato

Metestin®
DCI: Metenolone Enanthate · CAS: 303-42-4
100 mg/mL · Injectable oil solution

Description and mechanism of action

Methenolone enanthate is an anabolic steroid derived from dihydrotestosterone (DHT) with an additional double bond at the 1-2 position and a 1-methyl group. It is the enanthic ester of methenolone, conferring prolonged release after intramuscular injection.

It has an anabolic:androgenic ratio of 88:44 (ref. testosterone = 100:100). It does not aromatize to estrogens and has very low androgenic activity, making it one of the best-tolerated steroids. It promotes nitrogen retention, protein synthesis and has an immunostimulant effect. Indicated for catabolic states, sarcopenia, cachexia, osteoporosis and as an adjuvant in postoperative recovery.

Administration

RouteDeep intramuscular
Injection sitesGluteus maximus
FrequencyEvery 7 – 14 days
Therapeutic dose100 – 200 mg/week
VehicleCastor oil
PresentationMulti-dose vial 2 mL

Pharmacokinetics — Plasma half-life

Plasma half-life10 – 14 días
Peak serum level (Tmax)24 – 48 hours
Duration of action2 – 3 weeks
AromatizationNone
HepatotoxicityNone (non-17α-alkylated)
MetabolismHepatic (minimal first pass)
EliminationRenal
Detection time~5 weeks

Pharmacopoeia

ParameterSpecification
Molecular formulaC27H42O3
Molecular weight414.63 g/mol
Melting point67 – 71 °C
AppearanceWhite to slightly yellowish crystalline powder
SolubilityInsoluble in water; soluble in ethanol, oils, cloroformo
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.0%
SterilityCompliant (Ph.Eur. 2.6.1)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaPh.Eur., DAB (Pharmacopoeia Alemana)
Storage15 – 25 °C, protect from light
TA

Trembolona Acetato

TA-75
DCI: Trenbolone Acetate · CAS: 10161-34-9
75 mg/mL · Injectable oil solution

Description and mechanism of action

Trenbolone acetate is an anabolic steroid derived from 19-nortestosterone with conjugated double bonds at positions 9,11 and 11,12 (triene system). These modifications confer an androgen receptor affinity 3 to 5 times greater than testosterone and an anabolic:androgenic ratio of 500:500 (ref. testosterone = 100:100).

It does not aromatize to estrogens despite being a 19-nor derivative. It binds strongly to the AR and also interacts with the glucocorticoid receptor as an antagonist, reducing the catabolic effects of cortisol. It potently stimulates protein synthesis, nitrogen retention, hepatic and muscular IGF-1 production, and increases nutrient utilization efficiency.

Administration

RouteIntramuscular
Injection sitesGluteal, deltoid, vastus lateralis
FrequencyEvery 24 – 48 hours
Usual dose75 – 100 mg every 48h
VehicleSesame oil / MCT
Trenbolone has no approval for human use in any major pharmacopoeia. Its original use is veterinary (subcutaneous implants in cattle). BioNordet formulates it under GMP specifications as a pharmaceutical raw material for markets where its medical prescription is legal.

Pharmacokinetics — Plasma half-life

Plasma half-life1 – 1.5 days (24 – 36h)
Peak serum level (Tmax)6 – 12 hours
Duration of action2 – 3 days
AromatizationNone
Progestational activityModerate (affinity for PR)
MetabolismHepatic (epimerizations, oxidations)
EliminationRenal and biliary
Detection time~5 months

Pharmacopoeia

ParameterSpecification
Molecular formulaC20H24O3
Molecular weight312.41 g/mol
Melting point94 – 97 °C
Characteristic colorPale yellow crystalline powder (triene chromophore)
SolubilityInsoluble in water; soluble in oils, ethanol, chloroform
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.5%
SterilityCompliant (internal GMP specification)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaBP Vet, BioNordet internal monograph
Storage15 – 25 °C, protect from light (fotosensible)
EZ

Estanozolol

ST-25
DCI: Stanozolol · CAS: 10418-03-8
25 mg/mL · Injectable oil solution

Description and mechanism of action

Stanozolol is an anabolic steroid derived from DHT with a unique structural modification: the fusion of a pyrazole ring to the A-ring of the steroid skeleton, forming a stanozolol system (pyrazole[3,4:1,2]-androstan-17β-ol). Additionally, it has a 17α-methyl group that allows it to resist hepatic first-pass metabolism.

Anabolic:androgenic ratio of 320:30 (ref. testosterone = 100:100), one of the most favorable therapeutic indices among anabolic steroids. It reduces SHBG (sex hormone-binding globulin), increasing the free fraction of circulating testosterone. It does not aromatize to estrogens. It stimulates collagen synthesis and has fibrinolytic activity, making it useful in the treatment of hereditary angioedema and lipodystrophies.

Administration

Injectable routeIntramuscular (oil solution)
Injection sitesGluteal, deltoid
Injectable frequencyEvery 24 – 48 hours
Therapeutic IM dose25 – 50 mg/day
VehicleCastor oil / sesame oil
The BioNordet injectable stanozolol formulation is an oil solution, unlike the microcrystalline aqueous suspension used historically. The oil solution provides greater injection comfort and more sustained release of the active ingredient.

Pharmacokinetics — Plasma half-life

Half-life (injectable)~24 hours
Half-life (oral)4 – 5 hours
IM peak serum level12 – 24 hours
Oral bioavailability~50% (17α-alkylated)
AromatizationNone
HepatotoxicitySignificant (17α-alkylated)
MetabolismHepatic (conjugation, oxidation)
EliminationRenal (primary) and fecal
Detection time~2 months (injectable)

Pharmacopoeia

ParameterSpecification
Molecular formulaC21H32N2O
Molecular weight328.49 g/mol
Melting point229 – 242 °C (descomposición)
AppearanceWhite crystalline powder, odorless
SolubilityPractically insoluble in water; slightly soluble in ethanol
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.5%
Particle size (susp.)90% < 10 μm
SterilityCompliant (Ph.Eur.)
Pharmacopoeia de referenciaPh.Eur., USP, BP
Storage15 – 25 °C, protect from light
MD

Metandrostenolona

MD-25
DCI: Methandrostenolone / Metandienone · CAS: 72-63-9
25 mg/mL · Injectable oil solution

Description and mechanism of action

Methandrostenolone (methandienone, Dianabol®) is an anabolic steroid derived from testosterone with two key modifications: a 17α-methyl group to resist hepatic metabolism and a double bond at the 1,2 position that reduces its relative androgenicity.

Anabolic:androgenic ratio of 90-210:40-60 (ref. testosterone = 100:100). It binds to the androgen receptor and potently promotes protein synthesis, muscle glycogenesis and the retention of nitrogen, calcium, sodium, potassium and water. It moderately aromatizes to 17α-methylestradiol, an estrogen with greater activity than estradiol. The injectable version partially bypasses hepatic first pass, reducing hepatotoxicity but without completely eliminating it due to the presence of the 17α-methyl group.

Administration

Injectable routeIntramuscular
Oral route (classic)Oral tablets
IM frequencyEvery 24 – 48 hours
Usual IM dose25 – 50 mg/day
VehicleSesame oil / MCT
17α-alkylated compound: requires periodic hepatic monitoring (transaminases GOT/GPT, GGT, bilirubin). Avoid concomitant use with other hepatotoxic agents or alcohol.

Pharmacokinetics — Plasma half-life

Half-life (oral)4.5 – 6 hours
Half-life (injectable)6 – 8 hours
Oral peak serum level1 – 3 hours
Oral bioavailability~50%
AromatizationModerate (to 17α-methylestradiol)
HepatotoxicitySignificant (17α-alkylated)
Water retentionHigh (estrogen-dependent)
MetabolismHepatic (6β-hydroxylation, conjugation)
EliminationRenal (60-70%) and fecal
Detection time~6 weeks

Pharmacopoeia

ParameterSpecification
Molecular formulaC20H28O2
Molecular weight300.44 g/mol
Melting point163 – 167 °C
AppearanceWhite to off-white crystalline powder
SolubilitySlightly soluble in water; soluble in ethanol, chloroform
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.5%
SterilityCompliant (Ph.Eur.)
Pharmacopoeia de referenciaPh.Eur., BP
Storage15 – 25 °C, protect from light
OX

Oximetolona

Oximet-50
DCI: Oxymetholone · CAS: 434-07-1
50 mg/mL · Injectable oil solution

Description and mechanism of action

Oxymetholone is an anabolic steroid derived from DHT with modifications at the 17α position (methyl group) and 2-position (hydroxymethylene group). Despite being a DHT derivative, it exhibits paradoxical estrogenic activity by directly activating the estrogen receptor without enzymatic aromatization.

Anabolic:androgenic ratio of 320:45 (ref. testosterone = 100:100). It is one of the most potent oral anabolic steroids in terms of mass and strength gains. It intensely stimulates erythropoiesis (FDA-approved for aplastic, myelofibrotic and hemolytic anemias). It increases renal erythropoietin production and acts directly on erythroid precursors in bone marrow. The injectable version improves bioavailability and partially reduces hepatic burden.

Administration

Injectable routeIntramuscular
Oral route (classic)50 mg tablets
IM frequencyEvery 24 – 48 hours
Therapeutic dose (anemias)1 – 5 mg/kg/día
VehicleSesame oil / MCT
17α-alkylated compound with significant hepatotoxicity. It has been associated with hepatic peliosis (hemorrhagic cysts) and hepatocarcinoma with prolonged use. Requires strict hepatic monitoring: transaminases, bilirubin and periodic hepatic ultrasound. Maximum recommended use: 3–6 months.

Pharmacokinetics — Plasma half-life

Plasma half-life8 – 9 hours
Oral peak serum level2 – 4 hours
Oral bioavailability~95% (17α-alkylated)
AromatizationNone (direct estrogenic activity)
HepatotoxicityHigh (17α-alkylated)
Water retentionVery high
MetabolismHepatic (reduction, glucuronide conjugation)
EliminationRenal
Detection time~8 weeks

Pharmacopoeia

ParameterSpecification
Molecular formulaC21H32O3
Molecular weight332.48 g/mol
Melting point172 – 180 °C
AppearanceWhite to off-white crystalline powder
SolubilityPractically insoluble in water; soluble in ethanol, chloroform
Assay (HPLC)97.0 – 103.0%
Total impurities≤ 1.5%
SterilityCompliant (USP <71>)
Bacterial endotoxins< 10 UE/mL
Pharmacopoeia de referenciaUSP, BP
Storage15 – 25 °C, protect from light y humedad